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Abstract
Background: The mechanisms through which aberrant a-synuclein (ASYN) leads to neuronal death in Parkinson’s disease
(PD) are uncertain. In isolated liver lysosomes, mutant ASYNs impair Chaperone Mediated Autophagy (CMA), a targeted
lysosomal degradation pathway; however, whether this occurs in a cellular context, and whether it mediates ASYN toxicity,
is unknown. We have investigated presently the effects of WT or mutant ASYN on the lysosomal pathways of CMA and
macroautophagy in neuronal cells and assessed their impact on ASYN-mediated toxicity.
Methods and Findings: Novel inducible SH-SY5Y and PC12 cell lines expressing human WT and A53T ASYN, as well as two
mutant forms that lack the CMA-targeting motif were generated. Such forms were also expressed in primary cortical neurons,
using adenoviral transduction. In each case, effects on long-lived protein degradation, LC3 II levels (as a macroautophagy
index), and cell death and survival were assessed. In both PC12 and SH-SY5Y cycling cells, induction of A53T ASYN evoked a
significantdecreaseinlysosomal degradation,largely due toCMAimpairment.In neuronally differentiatedSH-SH5Ycells,both
WTand A53T ASYN inductionresulted ingradualtoxicity,whichwaspartlydependentonCMAimpairment and compensatory
macroautophagy induction. In primary neurons both WT and A53T ASYN were toxic, but only in the case of A53T ASYN did
CMA dysfunction and compensatory macroautophagy induction occur and participate in death.
Conclusions: Expression of mutant A53T, and, in some cases, WT ASYN in neuronal cells leads to CMA dysfunction, and this
in turn leads to compensatory induction of macroautophagy. Inhibition of these lysosomal effects mitigates ASYN toxicity.
Therefore, CMA dysfunction mediates aberrant ASYN toxicity, and may be a target for therapeutic intervention in PD and
related disorders. Furthermore, macroautophagy induction in the context of ASYN over-expression, in contrast to other
settings, appears to be a detrimental response, leading to neuronal death.
Citation: Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L (2009) Abberant a-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-
Mediated Autophagy. PLoS ONE 4(5): e5515. doi:10.1371/journal.pone.0005515
Editor: Howard E. Gendelman, University of Nebraska, United States of America
Received February 16, 2009; Accepted April 15, 2009; Published May 13, 2009
Copyright:  2009 Xilouri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported through an R21 grant (number NS055693) from the NINDS/NIH to KV and LS, a Greek Ministry of Education Post-Doctoral
Stipend Fellowship Award to MX, a Stipend Fellowship from BRFAA to TV and by grants to DP from the Canadian Institutes of Health Research. The funders had
no role in study design,data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lstefanis@bioacademy.gr
. These authors contributed equally to this work.
Introduction
a-Synuclein (ASYN) is an abundant neuronal protein closely
linked to Parkinson’s Disease (PD) pathogenesis [1–3]. Missense
mutations in the gene encoding ASYN [4–6] and multiplications of
the ASYN gene locus lead to familial cases of PD [7–9]. Even
sporadic PD cases are genetically linked to ASYN polymorphisms,
which may modulate ASYN transcription [10]. Furthermore, ASYN
is widelyconsideredto bethe main elementofLewyBodies(LBs) that
characterize PDpathologically [11]. ASYN deposition occurs early in
PD, before overt motor symptoms [12]. Aging in humans and
monkeys is associated with an increase of ASYN protein levels in the
substantia nigra, and this increase correlates with dopaminergic
dysfunction [13]. Cellular or animal models based on overexpression
of ASYN demonstrate neuronal dysfunction and, occasionally, death,
as well as inclusion formation and motor phenotypes [14]. These
data, in conjunction, have led to the idea that ASYN is linked to PD
through a toxic gain of function that is latent in the WT protein, and
is manifest when levels of WT ASYN increase, when point mutations
occur, or when WT ASYN is post-translationally altered, through
oxidation, nitration or other modifications [15].
Various theories have been proposed to explain this toxic gain
of function of ASYN. The feature that has attracted the most
attention is the propensity of ASYN to misfold, assume beta-sheet
structures, and fibrillize first into intermediate soluble ÆÆprotofi-
brillarææ or ÆÆoligomericææ species and then to mature fibrils.
Something along this aggregation pathway is posited to be toxic to
neuronal cells. The weight of the evidence favours the idea that the
intermediate oligomeric species are the main culprits [14]. Such
species could form pores on membranes of cells or intracellular
organelles, such as mitochondria or vesicles, or aberrantly interact
with cellular proteins, or, due to their abnormal structure, disrupt
normal cellular processes, such as ER-Golgi trafficking or
proteasomal degradation [14,16–20].
In prior work, we had noted that expression of mutant A53T
ASYN in PC12 cells led to accumulation of autophagic vacuoles
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lysosomal alterations may be a direct consequence of aberrant
ASYN expression [18]. A possible mechanism for this effect
emerged when we demonstrated in in vitro assays, using purified
ASYN protein and isolated liver lysosomes, that mutant A30P and
A53T ASYNs inhibit uptake and degradation of Chaperone-
Mediated Autophagy (CMA) substrates [21]. CMA is one of 3
major pathways of lysosomal degradation of intracellular proteins.
The other two are microautophagy and macroautophagy [22,23].
CMA involves the selective targeting of proteins containing a
KFERQ peptide motif to lysosomes. This requires binding to the
lysosomal receptor, Lamp2a, the rate-limiting step in CMA [24–
26]. In a more recent study, we have shown that WT ASYN is
degraded through CMA in human SH-SY5Y, rat PC12 cells and
primary neurons [27].
Despite the demonstration of CMA blockade by mutant ASYNs
in the in vitro assay with purified proteins and isolated liver
lysosomes, it remains unclear whether such blockade can be
conferred in a cellular context, and whether it could be responsible
for the lysosomal dysfunction that has been observed in certain
instances when ASYN is overexpressed. Furthermore, it is unclear
to what extent CMA blockade and resultant lysosomal alterations
could be related to the toxicity conferred by aberrant ASYN.
A related question concerns the role of macroautophagy in
ASYN-induced death. Reports in various cell systems and mice
have stressed the importance of macroautophagy for cell survival
in various neurodegenerative diseases and suggest induction of
macroautophagy as a therapeutic strategy, while other studies
suggest that suppression of macroautophagy is protective [28–35].
Furthermore, given that macroautophagy is also involved in
ASYN clearance [27,36], its enhancement has been proposed as
therapeutic strategy in PD.
In the current work, we have attempted to address these issues,
taking advantage of the creation of artificial mutants of ASYN that
are not targeted to the CMA pathway, and thus would not be
expected to compromise it. Apart from the role of CMA in ASYN-
mediated toxicity, we have also evaluated the role of macro-
autophagy in this process.
Results
CMA dysfunction is responsible for the decrease of total
lysosomal protein degradation in rat PC12 cell lines
inducibly expressing human A53T ASYN
We have previously shown that purified mutant ASYN inhibits
the in vitro uptake of CMA substrates in isolated lysosomes [21].
Furthermore, mutant ASYN expression impairs lysosomal acidi-
fication and lysosomal-dependent protein degradation in the PC12
cell model [18,21]. It has not been proven however that mutant
ASYN can induce CMA impairment in a cellular context, or that
this effect could lead to lysosomal dysfunction. To test this
hypothesis, we generated stable inducible Tet–off PC12 cell lines
overexpressing human A53T ASYN and lines expressing DDQ/
A53T ASYN. The DDQ mutant lacks the CMA targeting motif,
and was previously shown to lack CMA–dependent uptake into
lysosomes [21]; therefore, the double mutant DDQ/A53T should
not be targeted to the CMA pathway and, despite the presence of
the A53T mutation, should not inhibit it. The prediction, if the
hypothesis holds true, would be that, whatever the lysosomal
effects induced by A53T, they would not occur when DDQ/A53T
was expressed. We also used cells inducibly expressing WT ASYN
or bgal, which have been previously described [27]. Inducible
expression was found to be similar between cell lines (Figure 1A).
In order to measure and compare lysosomal function in these cell
lines, we employed the long lived protein degradation assay using
specific pharmacological inhibitors to discriminate between the
different forms of lysosomal degradation. In this manner we found
that cells expressing the A53T mutant form of ASYN exhibited
reduced total lysosomal protein degradation (inhibited by NH4Cl)
by ,30%. In contrast, the DDQ/A53T ASYN-expressing cells
showed no change (Figure 1B) and were at similar levels with those
in WT ASYN and control bgal expressing cells (Figure 1B). The
observed reduction in total lysosomal degradation could be
attributed to a possible reduction in macroautophagy or CMA,
as microautophagy is not thought to play a significant role in bulk
lysosomal protein degradation. However, the levels of macro-
autophagic degradation (inhibited by 3MA) were not altered in
any of the cell lines (Figure 1C). Additionally, there was no change
in the conversion of the cytoplasmic form of LC3 (LC3-I, 18 kDa)
to the preautophagosomal and autophagosomal membrane-bound
form of LC3 (LC3-II, 16 kDa) by western blot, an index of mature
autophagosomes (data not shown). Therefore, we conclude that
the reduction in total lysosomal degradation in the A53T ASYN
expressing lines is due to a reduction in CMA-dependent
degradation and to the presence of the CMA targeting motif.
We wished to examine whether the observed CMA-lysosomal
dysfunction induced by A53T ASYN expression could lead to
cellular toxicity. Induction of ASYN for at least 10 days in mitotic
PC12 cells had no obvious effect on cell survival, as judged by
Hoechst and Ethidium Homodimer co-staining (Supplementary
Figure S1A). Therefore, although induction of A53T ASYN causes
lysosomal impairment in cycling PC12 lines, this does not result in
increased cell death in this particular context.
CMA dysfunction is responsible for the decrease of total
lysosomal protein degradation in human SH-SY5Y cell
lines inducibly expressing human A53T ASYN
We went on to examine whether the A53T mutation has similar
effects on lysosomal protein degradation in human SH-SY5Y cell
lines. We generated stable inducible Tet–off SH-SY5Y cell lines
over-expressing human A53T ASYN or the DDQ/A53T ASYN
that lacks the CMA recognition motif. WT ASYN and bgal
expressing cells, reported previously [27], were also used.
Inducible expression was found to be similar between cell lines
(Figure 2A). We detected a significant reduction in the levels of
total lysosomal protein degradation (inhibited by Bafilomycin) by
,40% (+/2) in the A53T ASYN expressing cells (Figure 2B). In
contrast, DDQ/A53T ASYN expressing cells had similar levels of
total lysosomal protein degradation to the levels observed for WT
or bgal-expressing cells (Figure 2B). We observed no significant
changes in the levels of macroautophagic protein degradation
(inhibited by 3MA) (Figure 2C) or an increase in the levels of LC3-
II (data not shown). We therefore concluded that, similar to our
result with PC12 cells, the reduction in total lysosomal protein
degradation in A53T ASYN expressing human cell lines was also
due to CMA impairment. These lysosomal effects did not however
affect neuronal survival in these cycling cells (Supplementary
Figure S1B).
CMA impairment mediates lysosomal dysfunction in
neuronally differentiated SH-SY5Y cells expressing
human WT ASYN
We have previously found that upon neuronal differentiation
SH-SY5Y cells become vulnerable to WT ASYN-mediated
toxicity (Vekrellis et al., in press). We wished therefore to examine
the status of the lysosomal degradation system in this setting.
Accordingly, SH-SY5Y cells were differentiated with all trans
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induction of various forms of ASYN. In differentiated SH-SY5Y
cells expressing A53T ASYN we observed a substantial inhibition
of total lysosomal protein degradation, more dramatic than the
one detected in their cycling counterparts. In contrast to the
cycling cell model, macroautophagic protein degradation was also
severely compromised (Figure 3A, B). DDQ/A53T expression led
to a similar degree of lysosomal dysfunction as A53T. Therefore,
in this neuronally differentiated cellular setting, A53T seemed to
cause lysosomal damage that was more generalized and not
confined to CMA. Interestingly, despite the decrease of macro-
autophagy-dependent degradation, there was a significant increase
of the levels of LC3-II in A53T ASYN-expressing cells (Figure 3C),
suggesting that macroautophagosomes were accumulating. DDQ/
A53T ASYN expression, in contrast, did not lead to LC3-II
increase (Figure 3C).
In differentiated cells overexpressing WT ASYN, and in
contrast to their cycling counterparts, we detected a decrease in
the rate of total lysosomal protein degradation by ,40% that was
not observed in cells expressing DDQ/WT ASYN (Figure 3A).
Induction of WT ASYN resulted in increased levels of LC3-II
(Figure 3D), but without a significant increase of macroautophagic
protein degradation (inhibited by 3MA) (Figure 3B). These
phenomena were not observed in DDQ/WT ASYN-expressing
cells, indicating that in neuronally differentiated SH-SY5Y cells,
WT ASYN causes lysosomal alterations (general lysosomal
dysfunction and LC3-II induction) mainly due to CMA impair-
ment.
Figure 1. Over-expression of A53T ASYN in PC12 cells results in lysosomal dysfunction due to CMA impairment. (A) Generation of
stable inducible Tet-Off PC12 cell lines over-expressing human A53T and DDQ/A53T ASYN. Cells were cultured in the presence (+) or absence (2)o f
dox (2 mg/ml) for 4 days and assayed for ASYN expression with the C20 polyclonal Ab. ERK Ab is used as a loading control. (B, C) PC12 cells stably
transfected with WT or mutant ASYNs (A53T, DDQ/A53T) or control bgal were labeled with [
3H] leucine for 48 hrs (2 mCi/ml). Cells were treated with
or without NH4Cl (25 mM) or 3MA (10 mM) and degraded proteins were assayed 14 hrs later. Rate of total (B) (inhibitable by NH4Cl) and (C) of
macroautophagic (inhibitable by 3MA) long lived protein degradation in PC12 cell lines expressing bgal, WT, A53T or DDQ/A53T ASYN. For each line,
protein degradation was assessed in the presence or absence of dox, and the results are reported as percentage degradation in the absence
compared to the presence of dox (induced vs. non-induced). All presented data are the mean of 3 independent experiments and within each
experiment triplicate samples per condition were assessed. (***p,0.001, one way ANOVA followed by the Student-Newman-Keuls’ test, comparing
between cells expressing all forms of ASYN and bgal controls;
##p,0.01, comparing between cells expressing A53T and DDQ/A53T ASYN).
doi:10.1371/journal.pone.0005515.g001
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ASYNs in differentiated SH-SH5Y cells correlates with
CMA impairment and induction of macroautophagy
Our results in differentiated SH-SY5Y cells indicated that
induction of WT or mutant ASYN causes lysosomal dysfunction
and induction of autophagosome formation, as defined by LC3-II
accumulation. We wished to examine whether these effects could
be correlated with cell toxicity. In contrast to our observations in
proliferating cells, WT or A53T ASYN expression in neuronally
differentiated SH-SH5Y cells resulted in a gradual induction of
cell death (Figure 4A, B). The death induced by WT ASYN in this
context has been previously reported (Vekrellis et al., in press). The
rate of death was significantly reduced in DDQ/WT-expressing
compared to WT ASYN-expressing cells (Figure 4A), and was
slightly attenuated (with significance at one time point) in
DDQ/A53T ASYN-expressing compared to A53T ASYN-
expressing cells. These results suggest that CMA impairment
induced by WT ASYN expression is partly responsible for the
death observed in differentiated SH-SY5Y cells. In the case of
A53T, the contribution of CMA targeting to death was more
marginal, but still present.
As neuronal differentiation of our cultures resulted in increased
conversion of LC3-I to LC3-II following WT or A53T ASYN
induction (Figure 3C, D), we wanted to investigate the role of
macroautophagy in the observed cell death. We used the
pharmacological macroautophagy inhibitor 3-methyladenine
(3MA), or a small interfering RNA against the human autophagy
gene ATG 5 to inhibit macroautophagy in our cutures. 3MA was
added to the culture medium before death features started to
appear. 36 hours after 3MA addition we observed an increase in
the survival of differentiated WT ASYN expressing cells from
Figure 2. Over-expression of A53T ASYN impairs lysosomal function due to CMA targeting in proliferating SH-SY5Y cells. (A)
Generation of stable inducible Tet-Off SH-SY5Y cell lines over-expressing human A53T and DDQ/A53T ASYN. The cells were cultured in the presence
(+) or absence (2) of dox (3 mg/ml) for 4 days and assayed for ASYN expression with the C20 polyclonal Ab. ERK Ab is used as a loading control. (B, C)
SH-SY5Y cells stably transfected with WT or mutant ASYNs (A53T, DDQ/A53T) or control bgal were labeled with [
3H] leucine for 48 hrs (2 mCi/ml). Cells
were treated with or without Baf (500 nM) or 3MA (10 mM) in serum free medium and degraded proteins were assayed 14 hrs later. Rate of total (B)
(inhibitable by Baf) and (C) of macroautophagic (inhibitable by 3MA) long lived protein degradation in SH-SY5Y cells expressing bgal, WT, A53T or
DDQ/A53T ASYN. For each line, protein degradation was assessed in the presence or absence of dox, and the results are reported as percentage
degradation in the absence compared to the presence of dox (induced vs. non-induced). All presented data are the mean of 3 independent
experiments and within each experiment triplicate samples per condition were assessed. (***p,0.001, one way ANOVA followed by the Student-
Newman-Keuls’ test, comparing between cells expressing all forms of ASYN and bgal controls;
###p,0.001, comparing between cells expressing
A53T and DDQ/A53T ASYN).
doi:10.1371/journal.pone.0005515.g002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5515Figure 3. Over-expression of ASYNs impairs lysosomal function in differentiated SH-SY5Y cells, dependent on CMA targeting. (A, B)
SH-SY5Y cells expressing WT or mutant ASYNs were differentiated in 20 mM RA for 5 days in the presence or absence of dox and then treated as in
Figure 2. Rate of total (A) and (B) macroautophagy-dependent long lived protein degradation in differentiated SH-SY5Y cells expressing ASYN (WT,
DDQ/WT, A53T or DDQ/A53T). Bgal expressing cells are used as controls. For each line, protein degradation was assessed in the presence or absence
of dox, and the results are reported as percentage degradation in the absence compared to the presence of dox (induced/non-induced). All
presented data are the mean of 4 independent experiments and within each experiment triplicate samples per condition were assessed. (***p,0.001,
one way ANOVA followed by the Student-Newman-Keuls’ test, comparing between cells expressing all forms of ASYN and control bgal;
###p,0.001,
comparing between cells expressing WT and DDQ/WT ASYN). (C, D) Western blotting analysis of differentiated SH-SY5Y cells (7 days, +/2dox)
expressing A53T, DDQ/A53T, WT or DDQ/WT ASYN. ERK Ab is used as a loading control. Representative immunoblots of LC3 II are presented in the
left panels and quantification of LC3 II levels after ASYN induction (2dox compared to +dox) is shown in the right panels. All results are expressed as
the ratio of OD values to the corresponding controls and data are presented as mean of 6S.E. of 3 independent experiments [*p,0.05, Student’s t-
test comparing between cells expressing A53T and DDQ/A53T (C), or between cells expressing WT and DDQ/WT ASYN (D)].
doi:10.1371/journal.pone.0005515.g003
Lysosomal Effects of ASYN
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e551577.761.6% (WT–dox) to 95.264% (WT-dox+3MA) and similarly
in A53T ASYN expressing cells from 68.864% (A53T–dox) to
87.866% (A53T-dox+3MA) (Figure 4C). The DDQ/WT-express-
ing cells did not show any differences in survival+/23MA.
We have previously shown that inhibition of macroautophagy
with 3MA, leads to WT ASYN accumulation in cycling SH-SY5Y
cells [27] and we also observed an accumulation of WT and A53T
ASYN in differentiated cells (Supplementary Figure S2). There-
fore, 3MA exerts protective effects in this model, despite an
increase of ASYN levels.
Since autophagy requires the expression of autophagy genes
such as beclin-1, ATG 7 and ATG 5 to form autophagosomes
[37,38], we hypothesized that the suppression of ATG-5
expression will also decrease WT and A53T ASYN induced cell
death. In differentiated WT and A53T ASYN overexpressing cells
(8 days after RA addition), expression of ATG 5 was suppressed
with small interfering RNA (siRNA) against ATG-5 (Supplemen-
tary Figure S3). Neuronal survival was determined 72 hrs later as
described in Materials and Methods. ATG 5 siRNA significantly
decreased the level of WT and A53T ASYN-induced cell death
Figure 4. ASYN-induction is toxic to differentiated SH-SH5Y cells due to CMA blockade and macroautophagy induction. (A, B) ASYN
(WT, DDQ/WT, A53T or DDQ/A53T)-expressing SH-SH5Y cells, were differentiated in RA (+/2dox). Samples were collected at 5, 7, 9, 12, 14 days after
RA addition and survival was assessed by counting the number of intact nuclei. Rate of survival, presented in each case as the percentage of the (2)
over the (+) dox condition, is shown for WT/DDQ and WT ASYN (A), and for A53T/DDQ and A53T ASYN (B) cells. All presented data are the mean of 3
independent experiments. Within each experiment triplicate samples per condition were assessed. (*p,0.05, **p,0.01, ***p,0.001, Student’s t-test
comparing WT or A53T ASYN-expressing cells and their corresponding DDQ mutants). (C, D) Suppression of macroautophagy with 3MA (C) or with
ATG 5 siRNA (D), rescues differentiated SH-SY5Y cells from ASYN-induced death. (C) ASYN (WT, DDQ/WT, A53T)-expressing SH-SY5Y cells, were
differentiated (+/2dox) for 5 days before 3MA addition. 36 hrs later, survival was assessed as in A, B. (*p,0.05, student’s t-test, comparing WT or
A53T-expressing cells+/23MA). (D) WT or A53T ASYN cells and bgal cells were differentiated for 5 days (+/2dox) and transfected with scrambled (scr)
or ATG 5 siRNA together with EGFP. Cell death was assessed 72 hrs later by counting the percentage of EGFP-positive transfected cells that were also
Ethidium Homodimer-positive. At least 100 EGFP-positive cells were counted per well per condition. The data are presented as mean6SE of 3
independent experiments. Within each experiment triplicate samples per condition were assessed (
###p,0.001, one way ANOVA followed by the
Student-Newman-Keuls’ test, comparing WT or A53T ASYN cells+/2dox; *p,0.05, **p,0.01, comparing WT or A53T ASYN-induced cells (2dox)
transfected with ATG 5/EGFP to the control scr/EGFP transfected cells).
doi:10.1371/journal.pone.0005515.g004
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and A53T ASYN induce autophagic death in human differenti-
ated SH-SY5Y cells, a death that depends on the activation of
macroautophagy.
Adenoviral mediated over-expression of human A53T
ASYN in rat primary cortical neurons results in CMA
dysfunction, followed by a compensatory increase in
macroautophagy
We sought to examine whether over-expression of human WT
or mutant forms of ASYN impacts lysosomal function and
contributes to neuronal toxicity in primary cortical rat cultures.
These cultures provide a rich, homogeneous source of material of
CNS neurons, in which biochemical studies can be performed.
Cortical neurons are severely affected in synucleinopathies,
especially Lewy Body Dementia (LBD) and PD with Dementia
(PDD). For this purpose, we generated adenoviruses expressing
WT and A53T ASYN, as well as the two mutant forms (DDQ/
WT and DDQ/A53T) that lack the CMA-targeting motif and a
control virus expressing the EGFP protein. We transduced five
day-old cortical cultures with these viruses with multiplicities of
infection (MOIs) ranging from 50–150 for 24 h and first tested the
expression of human ASYN 24 to 96 h later by performing
immunostaining and immunoblotting with a specific antibody
against human ASYN (LB 509, data not shown). All forms of
ASYN were expressed in equally high levels, as assessed with a
polyclonal antibody that also recognizes endogenous ASYN
(Figure 5A). At longer exposures higher molecular weight species
were readily detectable in the lysates of ASYN transduced cortical
cultures and absent in control EGFP transduced neurons (data not
shown). We assessed the impact of the over-expression of various
forms of ASYN on protein degradation, as above, at 4 days and 1
week following viral transduction. When compared to EGFP-
transduced cultures, total long-lived protein degradation (inhibited
by NH4Cl) was not affected with transduction of any of the ASYN
constructs (Figure 5B). On the other hand, we observed a
significant induction of macroautophagic degradation (3MA-
dependent) in cultures expressing A53T ASYN, compared to
those expressing EGFP (Figure 5C). Furthermore, A53T ASYN
caused a significant reduction on CMA-dependent proteolysis
(Supplementary Figure S4). These effects did not occur when
DDQ/A53T ASYN was expressed, suggesting that the induction
of macroautophagy-dependent degradation by A53T ASYN
occurred secondary to CMA targeting. Macroautophagy induc-
tion by A53T ASYN was further confirmed by the conversion of
LC3-I toLC3-II (Figure 5D), which did not occur with DDQ/
A53T ASYN expression, consistent with the long-lived degrada-
tion results. The above results suggest that over-expression of
human A53T ASYN in primary neurons causes significant
reduction of CMA activity, which is followed by a compensatory
increase in macroautophagy, dependent on CMA targeting.
Over-expression of human ASYN is toxic to cortical
neurons
Many studies have reported that over-expression of human WT
or mutant ASYN in cultured primary neurons and animal models
is associated with reduced cell viability [39–42]. The availability of
the DDQ mutants enabled us to examine the issue of the
relationship of CMA dysfunction to ASYN toxicity in primary
neurons. We therefore investigated first whether the adenoviral
over-expression of WT or mutant ASYNs affects the survival of rat
cortical neurons. As shown in Figure 6A, over-expression of all
forms of ASYN resulted in significant reduction of cell viability of
cortical neurons (96 hours post-infection), compared to EGFP
overexpression, with A53T ASYN exhibiting the most toxic effect.
Interestingly, DDQ/A53T ASYN was significantly less toxic than
A53T ASYN, suggesting that CMA targeting may mediate some
of the aberrant effects of A53T ASYN. There was no significant
survival difference between WT and DDQ/WT ASYN
(Figure 6A).
As we had observed that A53T ASYN induces upregulation of
macroautophagy secondary to CMA targeting, we wished to
determine whether this induction of macroautophagy could be
related to the observed death. We therefore investigated whether
inhibition of macroautophagy could be protective. For this
purpose, we treated cortical neurons with 3MA (10 mM, 24 h)
following infection with EGFP, WT, A53T or DDQ/A53T ASYN
adenoviruses. Inhibition of macroautophagy improved the survival
of A53T ASYN-infected cortical cultures compared to A53T
ASYN alone, whereas 3MA application had no effect on the death
induced by the other ASYN forms (Figure 6B). Therefore, the
induction of macroautophagy by A53T ASYN expression
mediated in part cellular toxicity.
siRNA down-regulation of the autophagy related gene 5
(ATG 5) rescues human A53T ASYN-induced toxicity in rat
cortical neurons
From the aforementioned data it is evident that over-expression
of human A53T ASYN induces cell death in primary cortical
neurons, which can be attenuated by pharmacological suppression
of macroautophagy. Following a similar approach with the one in
differentiated SH-SY5Y neuroblastoma cells, and in order to
confirm this finding using a molecular approach, we targeted the
ATG 5 gene and examined whether the suppression of ATG 5
expression would also decrease A53T ASYN- induced cell death.
To down-regulate ATG 5, we designed a siRNA (ATG 5) to the
rat ATG 5 and a scrambled siRNA (scr), as a control. Because
cortical neurons are post-mitotic cells, the classic method for
siRNA delivery (with Lipofectamine) provides low transfection
efficiency. We therefore initially examined whether we could
sufficiently down-regulate ATG 5 in rat PC12 cells. When PC12
cells were transiently transfected with the ATG 5 siRNA, we
detected a significant down-regulation of endogenous ATG 5 by
almost 50% compared to cells transfected with the scr siRNA
(Supplementary Figure S5). As expected, induction of autophagy
with rapamycin (rap, 500 nM/24 h) increased LC 3-II levels in scr
siRNA transfected PC12 cells (scr+rap: 2.560.4, compared to scr
siRNA transfected untreated cultures 1.660.3), while, in the
presence of rapamycin, siRNA down-regulation of ATG 5
abrogated the induction of LC3-II levels (ATG 5+rap: 1.460.3,
compared to ATG 5 siRNA transfected untreated cultures
1.260.3) (Supplementary Figure S5). We then examined the
effects of siRNA ATG 5 down-regulation in rat cortical cultures.
We studied the impact of ATG 5 suppression on the formation of
green fluorescent protein (GFP)-LC3 vacuoles (characteristic of
autophagy). As shown in Figure 7A, ATG 5 siRNA down-
regulation in the presence of rapamycin suppressed the formation
GFP-LC3 vacuoles in cortical neurons (500 nM/48 h), while a
punctate distribution of GFP-LC3 was apparent in scr siRNA-
transfected cortical neurons treated with rapamycin, indicative of
authophagic vacuole formation. Subsequently, we transduced 5
days-old cortical neurons with the A53T ASYN adenovirus and
24 h later we transiently transfected them with scr or ATG siRNA
along with an EGFP vector to monitor transfection. ATG 5 down-
regulation was associated with a significant reduction in neuronal
death (8.561.5%, compared to 30.661.6% in scr siRNA
transfected cells) (Figure 7B). Taken together, these data indicate
Lysosomal Effects of ASYN
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5515Figure 5. Over-expression of A53T ASYN in primary cortical neurons alters lysosomal function dependent on CMA targeting. (A) Five
day-old cortical cultures were transduced with adenoviruses (MOI 150) expressing human ASYN (WT, DDQ/WT, A53T or DDQ/A53T) or EGFP (control
virus) as described in Materials and Methods. ASYN expression was assessed 96 hrs later by performing immunoblotting with the C20 polyclonal Ab.
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in rat primary cortical cultures that is dependent upon macro-
autophagy induction, which in turn occurs due to CMA
impairment.
Dopamine-modified ASYN affects lysosomal function and
survival of differentiated SH-SY5Y cells expressing WT
ASYN
The differential effects of WT ASYN on CMA and the
lysosomal system in the setting of neuronally differentiated SH-
SY5Y cells, compared to the other cellular systems utilized,
suggested to us that the dopaminergic phenotype of these cells may
play a modifying role. Previous reports have shown that
dopamine-modified WT ASYN, similar to the ASYN A53T and
A30P mutants, inhibits CMA activity by blocking its own uptake
and degradation, as well as the uptake and degradation of other
CMA substrates [43]. This modified form of ASYN is suggested to
be responsible for neuron toxicity and results from a non-covalent
interaction of ASYN and oxidized dopamine [44–46]. To examine
whether the aberrant effects of WT ASYN on lysosomal function
and survival in differentiated SH-SY5Y cells were mediated by
dopamine modification of ASYN, we used a-methyl-p-tyrosine
(AMPT), an inhibitor of tyrosine hydroxylase (TH), the enzyme
which is the rate-limiting step for dopamine production, and
analysed long lived protein degradation and cell death in cells
expressing WT ASYN. DDQ/WT ASYN-expressing cells were
used as control. Pharmacological inhibition of TH by AMPT led
to a significant recovery of lysosomal protein degradation (Fig. 8A),
as well as to an improvement on the survival of WT ASYN-
expressing cells (Fig. 8B). No such effects were seen in DDQ/WT
ASYN-expressing cells. Taken together, these data suggest that
dopamine modification of WT ASYN may in part be responsible
for the reduction in CMA function and increased toxicity.
Discussion
In the current study we have investigated the impact of WT and
mutant forms of ASYN on lysosomal pathways in neuronal cells,
as a possible pathogenetic mechanism for their toxic effects. For
this purpose we have generated inducible rat PC12 and human
SH-SY5Y cell lines expressing human WT and A53T ASYN, as
well as two mutant forms (DDQ/WT and DDQ/A53T) that lack
the CMA-targeting motif, and thus are not targeted to this
pathway, do not interact with Lamp2a, and do not interfere with
the degradation of other CMA substrates. We have used a similar
approach in cortical neurons, where we have overexpressed these
ASYN forms using adenoviral transduction.
In proliferating PC12 and SH-SY5Y cells, expression of A53T
ASYN caused CMA impairment, as indicated by the marked
decrease of total lysosomal degradation, in the face of unaltered
macroautophagic, i.e. 3-MA-dependent, degradation. The fact
that CMA impairment is responsible for lysosomal dysfunction in
this setting was confirmed by the lack of changes in lysosomal
Figure 6. Over-expression of human ASYN (WT, mutants) is toxic to rat cortical neurons. (A) Five days-old cortical cultures were
transduced with adenoviruses (MOI 150) expressing human ASYN (WT, DDQ/WT, A53T or DDQ/A53T) or EGFP (control virus) as described in Materials
and Methods. 96 hrs later cells were lysed with a nuclear-sparing buffer and intact nuclei were counted in a hemacytometer. (B) Cortical cultures were
treated as in A with slight modifications. 72 hrs post-infection, 3MA (10 mM) was added and intact nuclei were counted 24 hrs later. All data are
presented as mean6SE of independent experiments and within each experiment triplicate samples per condition were assessed. (*p,0.05, **p,0.01,
one way ANOVA followed by the Student-Newman-Keuls’ test, comparing between cultures expressing various forms of ASYN and control EGFP;
#p,0.05 comparing between cultures transduced with A53T and DDQ/A53T ASYN or between A53T ASYN transduced neurons+/23MA).
doi:10.1371/journal.pone.0005515.g006
ERK Ab is used as a loading control. A representative immunoblot of ASYN expression is shown. (B, C) Rate of total (inhibitable by NH4Cl) and of
macroautophagic (inhibitable by 3MA) long lived protein degradation in rat cortical cultures, 96 hrs after transduction with adenoviruses expressing
WT or mutant ASYNs. EGFP transduced neurons are used as controls. All presented data are the mean of 4 independent experiments and within each
experiment triplicate samples per condition were assessed. (D) Cortical neurons were treated as in B, lysed and assessed by western immunoblotting
for LC3 II levels. ERK Ab is used as a loading control. Representative immunoblot of LC3 II is presented in the left panel and quantification of LC3 II
levels after WT or mutant ASYN transduction is shown in the right panel. All results are expressed as the ratio of OD values to the corresponding
controls and all data are presented as mean of 6S.E. of 4 independent experiments (
*p,0.05, one way ANOVA followed by the Student-Newman-
Keuls’ test, comparing between cultures expressing various forms of ASYN and control EGFP;
#p,0.05, comparing between cultures transduced with
A53T and DDQ/A53T ASYN).
doi:10.1371/journal.pone.0005515.g005
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5515Figure 7. ATG 5 down-regulation decreases human A53T ASYN-induced death in rat cortical neurons. (A) Five day-old cortical cultures
were transfected with GFP-LC3 cDNA together with the scrambled (scr) or the ATG 5 siRNA. 24 hrs later, rapamycin was added (500 nM, 48 hrs) and
formation of GFP-LC3 vacuoles (dots) was determined by fluorescent microscopy. Representative fluorescent microscopic pictures showing the
formation of GFP-LC3 vacuoles (indicated by the arrow) in cultures transfected with the GFP-LC3 construct together with the scr siRNA after
rapamycin addition are shown. Vacuoles (dots) failed to be observed in rapamycin-treated cultures transfected with the GFP-LC3 construct together
with the ATG 5 siRNA. (B) Five day-old cortical cultures were transduced with A53T ASYN adenovirus and 24 hrs later were transiently transfected
Lysosomal Effects of ASYN
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5515degradation in cells expressing the double mutant DDQ/A53T.
These data show for the first time in a cellular context that
targeting of A53T ASYN to CMA is responsible for the decrease
of total lysosomal degradation in neuronal cells. Interestingly, in
these cycling cells, such lysosomal dysfunction was not associated
with cell death or with compensatory induction of macroauto-
phagy, as indicated also by the lack of changes in the ratio of LC3-
I to LC3-II.
The situation in cortical neuron cultures was somewhat
different, but still some essential features of the effects of A53T
ASYN on lysosomal pathways were confirmed in this primary
neuron setting. A53T ASYN again caused impairment of CMA,
although on this occasion this did not lead to global lysosomal
dysfunction, due to the compensatory activation of macroauto-
phagy, which was identified through two different assays, the
induction of 3MA-dependent degradation and the increase of the
LC3-II to LC3-I ratio. In this case therefore, the activation of
macroautophagy and the accumulation of autophagosomes were
‘‘productive’’, in that they led to degradation of substrate proteins
within lysosomes. A53T ASYN caused death that was in excess of
that conferred by WT ASYN, and this death, as well as the
macroautophagy induction, was abrogated with the double
mutant DDQ/A53T. These data raised the possibility that the
compensatory induction of productive macroautophagy may have
deleterious consequences. This hypothesis was confirmed through
pharmacological and molecular inhibition of this process, which
led to improved survival. Taken together, these data support the
concept that A53T ASYN causes toxicity in primary cortical
neurons in part through CMA dysfunction and resultant aberrant
macroautophagy activation. Thus, they confirm in a neuronal cell
context our original hypothesis that mutant ASYNs may confer
toxicity via CMA blockade [21], and for the first time provide
conclusive evidence that the compensatory activation of macro-
autophagy mediates death in this setting.
In neuronally differentiated SH-SY5Y cells, WT ASYN
expression overall led to similar effects with the expression of
A53T in cortical neuron cultures. As we have previously reported
(Vekrellis et al., in press), cell death occurred in this setting, unlike
the situation in the cycling cells. Death was associated with CMA
inhibition and increase of autophagosome formation, as assessed
by the conversion of LC3-I to LC3-II. However, in this case, this
was not associated with an increase of macroautophagy-dependent
degradation, and therefore represented ‘‘non-productive’’ macro-
autophagy. Lysosomal changes did not occur with expression of
the DDQ mutant, and death was significantly attenuated,
confirming that CMA inhibition played a role in these effects.
As in cortical neuron cultures with A53T ASYN expression,
survival was increased with pharmacological or molecular
inhibitors of macroautophagy. Therefore, even non-productive
macroautophagy can lead to neuronal death.
These data in neuronally differentiated SH-SY5Y cells are
important, because they indicate that, in certain settings, WT
Figure 8. Reduction of dopamine levels improves lysosomal dysfunction and survival of differentiated SH-SY5Y WT ASYN
expressing cells. (A, B) SH-SY5Y cells expressing WT or DDQ/WT ASYN were differentiated in RA (20 mM) in the presence (+) or absence (2) of dox
(3 mg/ml) for 5 days before addition of alpha-mehtyl-p-tyrosine (AMPT, 1 mM). Next, cells were labeled with [
3H] leucine for 48 hrs (2 mCi/ml) and
degraded proteins were assayed 14 hrs later. (A) Rate of total long lived protein degradation in differentiated SH-SY5Y cell lines expressing WT
ASYN+/2AMPT. DDQ/WT ASYN expressing cells are used as control. All data are presented as the relative percentage of long-lived protein
degradation in the (2) relative to the (+) dox setting for each condition (B) Cells expressing WT or DDQ/WT ASYN were differentiated as in A for 5
days and AMPT was added for subsequent 3 days. Survival was assessed by counting the number of intact nuclei and is presented as (2) relative to
(+) dox condition. All presented data are the mean of 3 independent experiments, and within each experiment triplicate samples per condition were
assessed. (*p,0.05, **p,0.01, ***p,0.001, one-way ANOVA followed by the Student-Newman-Keuls’ test, comparing between cells expressing WT
ASYN+/2AMPT, and between cells expressing WT and DDQ/WT ASYN).
doi:10.1371/journal.pone.0005515.g008
with the scr or ATG siRNA along with an EGFP construct to monitor transfection. Cell death was assessed 72 hrs later by counting the percentage of
EGFP-positive transfected cells that were positive for Ethidium Homodimer stain (dying cells). Representative pictures are shown in the upper panel
and quantification of the percentage of scr or ATG5/EGFP positive cells that were also stained with Ethidium Homodimer is shown in the bottom
panel. At least 100 EGFP-positive cells were counted per condition. The data are presented as mean6SE of 3 independent experiments (**p,0.01,
Student’s t-test, comparing A53T ASYN transduced neurons transfected with the scr or the ATG 5 siRNA. Bars: (A) 10 mM; (B) 50 mM.
doi:10.1371/journal.pone.0005515.g007
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cell death. This has also been suggested by Yang et al. [47] and
may relate to the fact that SH-SY5Y cells are dopaminergic, and
dopamine may form adducts with WT ASYN that can act as
CMA blockers in in vitro assays [43]. Consistent with this idea, our
results suggest that inhibition of dopamine synthesis in this cell
system leads to restoration of lysosomal function and improved
survival (Fig. 8). This is significant, given that in the vast majority
of PD patients it is the WT protein that is implicated as the
pathogenetic agent.
Expression of A53T ASYN in neuronally differentiated SH-
SY5Y cells led to more profound lysosomal dysfunction and
accelerated death compared to WT ASYN expression. As with the
WT protein, LC3-II accumulated, and this accumulation did not
occur when the double mutant DDQ/A53T was expressed.
However, A53T ASYN expression led also to profound inhibition
of macroautophagy-dependent degradation, and this effect was
not attenuated when DDQ/A53T was expressed. DDQ/A53T
expression was marginally less toxic than A53T ASYN. These
results suggest that A53T in this setting may also affect lysosomal
function independent of CMA, through yet unknown mechanisms.
It is worth noting that WT and mutant ASYNs are toxic to
differentiated but not proliferating neuroblastoma cells. The
factors accounting for this difference could include subtle
differences in the generated ASYN species, differences in clearance
mechanisms, or involvement of cell cycle molecules or other
proteins differentially expressed in the two states. It is possible that
the lysosome plays a greater role in the degradation of proteins in
the differentiated compared to the proliferating state. In support of
this, total long lived lysosomal degradation (inhibited by Baf) in the
cycling cells was detectable only after removal of serum from the
medium (data not shown), suggesting that in their normal state
these cells rely very little on lysosomes for protein turnover.
Furthermore, the degree of lysosomal dysfunction caused by both
WT and A53T ASYN is more prominent in the differentiated
cells, and it is only in these cells that we detected LC3-II
accumulation. Therefore, specific effects on lysosomes may
mediate the preferential toxicity of aberrant ASYN in the
neuronally differentiated state.
From our results, it appears that, depending on the exact
context, CMA inhibition conferred by aberrant ASYN may, or
may not, lead to induction of the process of macroautophagy.
Massey et al. [48] were the first to report that specific CMA
inhibition may lead to activation of macroautophagy, and we have
also confirmed it [27]. In our current experiments, this effect, as
assessed by LC3-II accumulation, occurred in cortical neurons and
in differentiated SH-SY5Y cells, but not cycling cells. The reasons
for these differences and the mechanisms through which such
compensatory activation of macroautophagy occurs are unclear. It
is worth noting however that in every case in which we observe
such compensatory activation of macroautophagy, defined again
as an increase of LC3-II to –I ratio, there is cell death, and this
death is attenuated by macroautophagy inhibition.
This raises the issue of the exact nature of the lysosomal effects
of aberrant ASYN that are linked to toxicity. In contrast to
macroautophagy induction which, as mentioned above, correlates
with toxicity, lysosomal dysfunction (as defined by impairment of
lysosomal-dependent long-lived protein degradation) does not. For
example, no generalized lysosomal dysfunction occurs in cortical
neurons, and yet there is lysosome-dependent death, and the
converse is true in cycling cells. However, in cases where profound
generalized lsysomal dysfunction occurs (the case of A53T ASYN
expression in differentiated SH-SY5Y cells), this does appear to
influence cell viability. It would appear therefore that autophago-
some production/formation, and not general lysosomal dysfunc-
tion, is mainly responsible for the toxicity observed following CMA
inhibition by aberrant ASYN (Fig. 9). As mentioned, autophago-
some formation can exert toxicity regardless whether it leads to
‘‘productive’’ macroautophagy or not. Therefore, the toxic event
appears to be the formation and accumulation of autophagosomes,
and not their fusion with lysosomes or the excess degradation of
substrate proteins. Such toxic effects could be related to
progressive damage and destabilization of the membranes of the
accumulating autophagic vacuoles, leading to the cytoplasmic
release of vacuolar hydrolases and cell death [49,50], or to
impaired vesicular transport [51].
The role of macroautophagy in cell homeostasis remains
controversial since macroautophagy contributes to cell survival
under stress such as starvation, but can also contribute to cell
death [37]. In particular as regards to neurodegeneration, this can
apparently be induced both by lack and by excess of macro-
autophagy [52,53] Regarding alpha-synucleinopathies, data,
including our own [27,36] and data presented here in supple-
mentary Figure S2, suggest that various forms of ASYN may be
degraded by this process, and that, therefore, a strategy of
macroautophagy induction may be beneficial in terms of removing
such aberrant species and thus preventing their toxic effects [29].
The data presented here though would argue that this represents
Figure 9. Schematic diagram of the lysosomal effects and relevant cell death pathways induced by aberrant ASYN. Aberrant ASYN
induces in all settings CMA dysfunction. When this leads to compensatory macroautophagy induction (as assessed by autophagosome formation/
accumulation), autophagic cell death, inhibited by macroautophagy inhibitors, occurs. In certain settings (A53T ASYN in neuronally differentiated SH-
SY5Y cells), lysosomal dysfunction occurs independent of CMA targeting and may contribute to death (dotted arrows).
doi:10.1371/journal.pone.0005515.g009
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begin to exert toxic effects, they may do so in part via
macroautophagy activation, and therefore further pharmacolog-
ical macroautophagy activation may potentiate these effects.
It is worth noting in this context that toxicity induced by another
genetic aberration leading to PD, that of mutant leucine rich repeat
kinase 2 (LRRK2), has also been linked to macroautophagy
induction. Inhibition of macroautophagy in differentiated SH-
SY5Y cells reversed the detrimental effects of mutant G2019S
LRRK2 on neuronal process length [54]. Decrease on neuronal
process length represents a prominent feature of the degenerative
phenotype associated with PD-associated LRRK2 mutations.
Therefore, activation of macroautophagy may represent a more
generalmechanismthroughwhichaberrantformsofproteinslinked
to PD cause neurodegeneration.
We do not wish to imply that the lysosomal alterations
presented here represent the only mechanisms through which
ASYN exerts its toxicity. It is clear that this is part of the picture
and that other processes play a role. Interestingly, monomeric
ASYN is sufficient to exert CMA blockade [21,43], and therefore
the effects observed here cannot be accounted for by ‘‘fibrils’’ or
‘‘oligomers’’. Other cellular effects mediated by such species may
also be important for ASYN toxicity, as we and others have shown
[55] (Vekrellis et al., in press). Despite this, it is obvious that
targeting the CMA pathway may provide some therapeutic
benefits in PD. Improving CMA function may not only serve to
accelerate ASYN degradation, but also to mitigate potential
deleterious consequences of aberrant ASYN on this system.
Materials and Methods
Generation of stable cell lines and transfections
Stable rat PC12 (Clontech) and human SH-SY5Y (gift from Dr.
Darryl Yamashiro, Dept. of Pediatrics, Columbia University,
USA) cells inducibly expressing human WT and DDQ/WT
ASYNs, were generated as previously described [27]. Cells
expressing human A53T and DDQ/A53T ASYNs were generated
with similar procedures.
Cell culture
PC12 cells were cultured in RPMI 1640 (Invitrogen) with 10%
Horse Serum (Biowest) and 5% Fetal Bovine Serum (FBS,
Biowest.) on collagen coated plates. SH-SY5Y cells were cultured
in RPMI 1640, 10% FBS. Stable cell lines were cultured with
200 mg/ml G418 and 25 mg/ml (PC12 cells) or 50 mg/ml (SH-
SY5Y cells) Hygromycin B (Roche). Differentiation of SH-SY5Y
cells was with all-trans Retinoic Acid (RA, 20 mM, Sigma). For
pharmacological studies 3-Methyladenine (3MA, Sigma-Aldrich),
NH4Cl (Sigma-Aldrich), Bafilomycin (Baf, Sigma-Aldrich), alpha-
methyl-p-tyrosine (AMPT, Sigma-Aldrich) and doxycyclin (dox,
Clontech) were added at indicated times and concentrations.
Primary neuronal cultures
Cultures of rat (embryonic day 18, E18) cortical neurons were
prepared as previously described [56,57]. Cells were plated onto
poly–D-lysine-coated dishes at a density of approximately
150.000–200.000/cm
2 and maintained in Neurobasal medium,
with B27 supplement (Invitrogen), L-glutamine (0.5 mM) and
penicillin/streptomycin (1%). More than 98% of the cells cultured
under these conditions represent post-mitotic neurons [58].
Intracellular protein degradation
Total protein degradation was measured by pulse-chase
experiments as previously described [27]. Proteolysis was expressed
as the percentage of the initial total acid-precipitable radioactivity
(protein) in the cell lysates transformed to acid soluble radioactivity
(amino acids and small peptides) in the medium during the
incubation. Total lysosomal degradation was estimated as the
NH4Cl- or Baf- inhibited degradation, while macroautophagic
degradation was estimated as the 3MA-inhibited proteolysis.
Cell Death
Cultures were exposed to Ethidium Homodimer (1 mM,
Molecular Probes), which labels dead cells, and Hoechst 33342
(1 mM; Sigma), which labels cell nuclei. The percentage of dead
cells, (Ethidium Homodimer-positive over total Hoechst-positive
nuclei), was assessed in three separate wells, counting at least 100
cells per well.
For neuroprotection assays 3MA (10 mM, 36 hrs) or alpha-
mehtyl-p-tyrosine (AMPT, 1 mM) were added 5 days after RA
addition.
Assessment of survival. Viable cells were quantified by
counting the number of intact nuclei in a haemocytometer, after
lysing the cells in a detergent-containing solution [59,60]. This
method has been shown to be reproducible and accurate and to
correlate well with other methods of assessing cell survival-death
[56,61]. Cell counts were performed in triplicate and are reported
as means6SE.
Generation of Recombinant Adenovirus
The recombinant adenoviral vectors expressing various forms of
ASYN were constructed using the AdEasy system as previously
described [62].
For primary cell infections, viruses (MOI 150) were added to
primary cortical cultures 5 days after plating.
RNAi
Small interfering RNAs were designed against human and rat
ATG 5 mRNAs according to the criteria of Elbashir et al [63] and
Reynolds et al [64]. The nucleotide sequences targeting ATG 5
were: 59-AACCTTTGGCCTAAGAAGAAA-39 (human) and 59-
AAGTCAGGTGATCAACGAAAT-39 (rat). As controls, all Star
Negative Control siRNA (#1027281, Qiagen) and a scrambled
(scr) siRNA containing the sequence 59-AACGAGAAGCA-
GAGCCATACT-39 were used respectively.
siRNAs at a concentration of 25 nM were delivered with
Lipofectamine 2000 (Invitrogen) to differentiated SH-SY5Y or
PC12 cells. ATG 5 down-regulation was assessed 72 h post-
transfection. Cortical neurons were infected with the human A53T
ASYN adenovirus for 24 hours. The next day, the medium was
removed and neurons were transfected with the rat ATG 5 or the
scr siRNA together with EGFP plasmid (to monitor transfection
efficiency) for 6 hours. 72 hours post-transfection, cells were
treated with Ethidium Homodimer (1 mM, 15 min, 37uC) in
combination with Hoechst 33342 (1 mM, Sigma). Neurons were
fixed in 3.7% formaldehyde and death was estimated by assessing
the percentage of EGFP/ATG 5 or EGFP/scr siRNA positive
(green) cells which were Ethidium Homodimer-positive (red). To
verify that the rat ATG 5 siRNA is functional in cortical neurons,
we have used a GFP-LC3 plasmid that allows monitoring of LC3 I
to II conversion (kind gift of Tamotsu Yoshimori, National
Institute of Genetics, Japan). Cortical neurons were co-transfected
with the scr or the ATG 5 siRNA along with the GFP-LC3
construct. Twenty four hrs post-transfection, autophagy was
induced by addition of rapamycin (500 nM, 48 h) and cultures
were observed under a fluorescent microscope for the formation of
autophagic vacuoles.
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Western blotting was performed as described previously [27].
Membranes were probed with antibodies against: 1) ASYN,
polyclonal C20 (1:1000; Santa Cruz), 2) polyclonal ERK (1:5000;
Santa Cruz), 3) polyclonal LC3 (1:1000, Molecular Probes), 4)
polyclonal ATG 5 (1:1000, Sigma). Blots were probed with HRP-
conjugated secondary antibodies (Jackson). Intensity of immuno-
reactive bands was estimated by densitometric quantification using
the Gel analyzer v1.0 software.
Statistical analysis
All data are expressed as mean6SE. Statistical significance of
differences was evaluated either with Student’s t-test or with one
way ANOVA followed by the Student-Newman-Keuls’ test.
Probability values ,5% were considered significant.
Supporting Information
Figure S1 WT or mutant ASYN-induction in cycling PC12 or
SH-SY5Y cell lines doesn’t affect cell survival. Proliferating PC12
(A) or SH-SY5Y (B) cells were induced to express (2dox) WT or
mutant ASYNs for 10 days and then stained with Propidium Iodide
(1 mM), which labels dying cells. Cell nuclei were counterstained
with the Hoechst 33342 dye. Quantification of the percentage of
dying cells stained with Propidium Iodide compared to the total
numberofHoechst-positivenucleiisdepicted.Atleast100 Hoechst-
positivecellswerecountedperwellpercondition.Allpresented data
are the mean of 3 independent experiments and within each
experiment triplicate samples per condition were assessed.
Found at: doi:10.1371/journal.pone.0005515.s001 (1.64 MB
DOC)
Figure S2 Inhibition of macroautophagy increases human over-
expressed WT and A53T ASYN levels in differentiated SH-SY5Y
cells. SH-SY5Y cells expressing WT or A53T ASYN were
differentiated with 20 mM Retinoic Acid (RA) for 5 days in the
absence of dox. 3MA (10 mM) was added to the cultures for
36 hrs. Untreated cells were used as controls (ctrl). Cell lysates
were assessed by western immunoblotting for ASYN levels. ERK
Ab was used as a loading control. (A, B) Representative
immunoblots of ASYN levels in WT (A) and A53T (B) expressing
cells. (C) Quantification of WT or A53T ASYN levels after 3MA
addition, compared to controls. Results are expressed as the ratio
of OD values to the corresponding controls and data are presented
as the mean6S.E. of 3 independent experiments (**p,0.01,
student’s t-test comparing 3MA treated cells with the controls).
Found at: doi:10.1371/journal.pone.0005515.s002 (2.08 MB TIF)
Figure S3 Down-regulation of human ATG 5 in differentiated
WT and A53T ASYN expressing SH-SY5Y cells. SH-SY5Y cells
expressing WT or A53T ASYN were differentiated with 20 mM
Retinoic Acid (RA) for 5 days in the absence of dox and then
transfected with ATG 5 or scrambled (scr) siRNA. Seventy two hrs
later, cells were lysed and assayed for ATG 5 expression. ERK Ab
was used as a loading control. (A, B) Representative immunoblots
of ATG 5 levels in WT (A) and A53T (B) expressing cells. (C)
Quantification of ATG 5 levels in cells transfected with ATG 5
compared to cells transfected with scr siRNA. Results are
expressed as the ratio of OD values to the corresponding controls
and data are presented as mean of 6S.E. of 3 independent
experiments (*p,0.05, student’s t-test comparing ATG 5 siRNA
with the control scr siRNA treated cells).
Found at: doi:10.1371/journal.pone.0005515.s003 (2.09 MB
DOC)
Figure S4 Over-expression of A53T ASYN in primary cortical
neurons causes CMA dysfunction. Rate of CMA-dependent [the
difference between NH4Cl (total lysosomal) and 3MA (macroauto-
phagy)-dependent] long lived protein degradation in rat cortical
cultures, 96 hrs after transductionw i t ha d e n o v i r u s e se x p r e s s i n g
A53T or DDQ/A53T ASYN. EGFP transduced neurons are used as
controls. All presented data are the mean of 4 independent
experiments and within each experiment triplicate samples per
condition were assessed (*p,0.05, one way ANOVA followed by the
Student-Newman-Keuls’test,comparingbetweenculturesexpressing
A53T ASYN and control EGFP; #p,0.05, comparing between
cultures transduced with A53T and DDQ/A53T ASYN).
Found at: doi:10.1371/journal.pone.0005515.s004 (1.42 MB TIF)
Figure S5 Down-regulation of rat ATG 5 in PC12 cells
suppresses macroautophagy induction in the presence of rapamy-
cin. Naive PC12 cells were transfected with ATG 5 or scrambled
(scr) siRNA. Forty eight hrs after siRNA transfection rapamycin
(rap, 500 nM) was added to the cultures. Seventy two hrs post-
transfection, cells were lysed and assayed for ATG 5 and LC 3
levels. ERK Ab was used as a loading control. Representative
immunoblots of ATG 5 and LC 3 in the presence or absence of
rapamycin (rap) are presented in the upper panel. ATG 5 and LC 3
II levels in cells transfected with ATG 5 were compared to cells
transfected with scr siRNA. Results are expressed as the ratio of OD
valuestothecorresponding controlsanddataarepresentedasmean
of 6S.E. of 4 independent experiments (*p,0.05, **p,0.01, one
way ANOVA followed by the Student-Newman-Keuls’ test,
comparing ATG 5 levels in ATG 5 siRNA with the control scr
siRNA-treated cells; #p,0.05, comparing LC3 II levels in ATG 5
siRNA with the control scr siRNA treated cells+/2rapamycin).
Found at: doi:10.1371/journal.pone.0005515.s005 (2.66 MB TIF)
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